Evidence map›Paper›PMID 42675479›Full record

ArticleRespiratory research2026

Irisin maintains ER homeostasis and activates AMPK via integrin αVβ5 to attenuate CSE + LPS-induced emphysema and inflammation.

Zina Bai, Tongxinwei Sun, Zelin Chen, Siqin Han, Jingwen Li, Xiaopeng Zhang, Cuiqing Ma, Yahong Chen, Ping Jiang, Xixin Yan and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zina BaiThe Third Department of Pulmonary and Critical Care Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Tongxinwei SunThe Third Department of Pulmonary and Critical Care Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Zelin ChenThe Third Department of Pulmonary and Critical Care Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Siqin HanThe First Department of Pulmonary and Critical Care Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Jingwen LiThe First Department of Pulmonary and Critical Care Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Xiaopeng ZhangDepartment of Thoracic Surgery, Hebei General Hospital, Shijiazhuang, Hebei, China.
Cuiqing MaDepartment of Immunology, Key Laboratory of Immune Mechanism and Intervention On Serious Disease in Hebei Province, Hebei Medical University, Shijiazhuang, Hebei, China.
Yahong ChenDepartment of Pulmonary and Critical Care Medicine, Peking University Third Hospital, Beijing, China.
Ping JiangDepartment of Pulmonary and Critical Care Medicine, Tianjin First Central Hospital, Tianjin, China.
Xixin YanThe First Department of Pulmonary and Critical Care Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Aihong MengThe Third Department of Pulmonary and Critical Care Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. mah123@hebmu.edu.cn.

Funding

Government-funded Clinical Medicine Talent Training ZF2026107Hebei Natural Science Foundation Joint Research Program for Basic Science Cooperation in the Beijing-Tianjin-Hebei Region H2023206909/J230030/S23ZX16013Hebei Provincial Health Commission, Hebei Red Cross Society, Hebei Province Medical Research and Enterprise Joint Innovation Special Project LH20250082Natural Science Foundation of Hebei Province H2019206263
6 · The paper itself

Abstract

backgroundAECOPD adversely affects patient survival rates and overall quality of life. Irisin is being increasingly recognized for its therapeutic potential in attenuating pulmonary injury, but its underlying mechanism remains unclear.

methodsHuman lung tissue samples were subjected to IHC analysis for irisin, integrin αVβ5, and GRP78 expression. CSE+LPS-induced mouse and cell models were used to investigate whether irisin protects against emphysema and inflammation by regulating ER homeostasis and AMPK activity via integrin αVβ5.

resultsIn COPD patients, irisin levels are decreased, whereas integrin αVβ5 and GRP78 levels are elevated. Irisin improved lung function and attenuated emphysema and inflammation in mice, and these effects were abolished by cilengitide. Irisin directly bound to integrin αVβ5, maintained ER homeostasis via the PERK/ATF4/CHOP pathway, and activated AMPK. These protective effects were lost upon integrin αVβ5 knockdown.

conclusionThese findings suggest that through integrin αVβ5, irisin concurrently maintains ER homeostasis and activates AMPK, thereby alleviating CSE+LPS-induced emphysema and inflammation, suggesting a novel therapeutic direction for the management of AECOPD.

Indexed as

AMP-Activated Protein KinasesEndoplasmic ReticulumFibronectinsHomeostasisPulmonary EmphysemaReceptors, VitronectinAnimalsEndoplasmic Reticulum Chaperone BiPEnzyme ActivationFemaleHumansInflammationIntegrinsLipopolysaccharidesMaleMiceAMP-Activated Protein KinasesEndoplasmic Reticulum Chaperone BiPFibronectinsFNDC5 protein, mouseHSPA5 protein, humanHspa5 protein, mouseintegrin alphaVbeta5IntegrinsITGA5 protein, humanLipopolysaccharidesReceptors, VitronectinAMPKEmphysemaER stressInflammationIntegrin αVβ5Irisin

Identifiers

PMID42675479
PMCPMC13528041

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.